AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...

Plaque Psoriasis BURLINGAME, CA, UNITED STATES, January 27, 2025 /EINPresswire / -- The worldwide Plaque Psoriasis <a target=_blank href=h ...

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...

Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Overweight rating on ...

Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the ...

What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing ...